

UCSF

UC San Francisco Previously Published Works

Title

Renalase levels are decreased in maternal blood and placental tissues in pregnancies associated with preterm preeclampsia.

Permalink

<https://escholarship.org/uc/item/5f88r850>

Journal

Scientific Reports, 15(1)

Authors

Soliman, Youstina

Eke, Chino

Guo, Xiaojia

et al.

Publication Date

2025-02-22

DOI

10.1038/s41598-025-90524-z

Peer reviewed



OPEN Renalase levels are decreased in maternal blood and placental tissues in pregnancies associated with preterm preeclampsia

Youstina Soliman^{1,4,8}, Chino Eke^{1,8}, Xiaojia Guo², Melinda Wang^{2,5}, Tatiana Silva¹, Gary V. Désir^{2,6} & Liza Konnikova^{1,3,7}✉

Preeclampsia (PEC) is a complication of pregnancy associated with hypertension and the risk of eclampsia. The pathophysiology of PEC is unknown and identifying factors associated with PEC during pregnancy is crucial for placental, fetal, and maternal health. Renalase (RNLS) is an anti-inflammatory secretory flavoprotein associated with hypertension. Recent data demonstrated a correlation between maternal serum RNLS and PEC, and work from our group identified RNLS expression in the placenta. However, it remains unknown whether RNLS levels in placenta are altered by preeclampsia. Additionally, it is unclear if there is a differential effect of preterm and term PEC on RNLS. We demonstrate that serum RNLS was reduced in preterm cases of PEC. Similarly, placental RNLS was diminished in the chorion of preterm cases of PEC. However, a reduction of RNLS in the decidua was observed with all cases of PEC, while the levels of RNLS within the placental villi were similar in all cases. Overall, we demonstrate that RNLS correlates with PEC both systemically in maternal serum and locally within the placenta, with variable effects on the different layers of the placenta and more pronounced in preterm cases.

Keywords Preeclampsia (PEC), Renalase (RNLS), Placenta, Maternal serum

Preeclampsia (PEC) is a severe complication of pregnancy that affects 3–5% of global pregnancies and is one of the four leading causes of maternal death in the United States^{1,2}. Although the exact mechanism remains elusive, the disease emanates from the maternal–fetal interface and is characterized by hypertension alongside proteinuria after 20-week gestation, and in severe cases, progresses to eclampsia^{2,3}. For the fetus, preeclampsia can lead to growth restriction, oligohydramnios, and preterm birth^{4,5}. The only known definitive treatment for PEC is delivery¹. However, anti-hypertensive treatments that regulate blood pressure can ameliorate the symptoms³.

Renalase (RNLS) is an anti-inflammatory secretory flavoprotein present in plasma, initially identified in the kidneys. It has since been found in several tissues, including the heart⁶, pancreas⁷, and most recently by our group in the placenta⁸. Two forms of RNLS have been previously identified in plasma. The native form represents the active fraction (4%) of plasma RNLS and the acid-sensitive form represents the protein-bound portion which is the inactive form of RNLS held in reserve²¹. Previous studies have demonstrated that RNLS levels are reduced in hypertension and kidney disease. Interestingly, several studies have also suggested a reduction in maternal serum levels of RNLS in preeclampsia^{9–12}. Our group demonstrated that RNLS is expressed in all layers of the placenta, with a notable abundance in trophoblasts and Hofbauer cells, specialized placental macrophages⁸. However, it remains unknown whether RNLS level in placental tissue is altered in preeclampsia and if this is specific to the various layers of the placenta. Moreover, it is also unclear if RNLS is differentially expressed in the maternal serum and placental tissue of preterm and term preeclampsia cases.

¹Department of Pediatrics, Yale University School of Medicine, New Haven, CT, USA. ²Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA. ³Department of Immunobiology, Yale University School of Medicine, New Haven, CT, USA. ⁴Department of Medical Sciences Frank H. Netter MD School of Medicine at Quinnipiac University, North Haven, CT, USA. ⁵Department of Internal Medicine, University of California San Francisco, San Francisco, CA, USA. ⁶VA CT Medical Center, Yale University, New Haven, CT, USA. ⁷Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, 375 Congress Ave, LSOG 405B, New Haven, CT 06519, USA. ⁸Youstina Soliman and Chino Eke are equal co-first authors. ✉email: liza.konnikova@yale.edu

The placenta is a critical transient organ that develops during early gestation to support the growing fetus. As the interface between the mother and fetus, it regulates the exchange of nutrients, growth factors, hormones, and other immunologic factors necessary for maintaining a healthy pregnancy^{13,14}. The placenta develops in a highly organized fashion, regulated by several hormones whose expression changes throughout pregnancy¹⁴. Dysregulation in placental development can lead to abnormal placentation during early gestation increasing the likelihood of perinatal morbidity and mortality^{14,15}.

This temporary, but vital organ, is composed of several layers that ensure its proper function. The fetal membranes include the amnion and chorion derived from the chorionic sac while the maternal membrane is known as the decidua¹⁶. The chorion consists of a membrane bilayer composed of trophoblasts and the extraembryonic mesoderm which forms the barrier separating the maternal intervillous space from fetal circulation^{13,17}. The decidua is comprised primarily of endometrial stromal cells and maternal vascular cells¹⁸. Finally, the placental villi consist of syncytiotrophoblasts, cytotrophoblasts, and villous core stromal cells¹⁹ and exist between the fetal membranes and the decidua forming a highly vascularized space that enables the bidirectional exchange of resources between the mother and fetus²⁰.

In the current study, we explore if PEC correlates with RNLS levels in maternal serum, decidua, placental villi, or the fetal membranes. To do so, we performed ELISAs on a cohort of 28 maternal serum samples and immunohistochemistry on 19 cases of preterm and term births with and without preeclampsia. By combining maternal samples with the fetus derived placenta, we hope to further elucidate the impact of PEC on RNLS. Our findings, consistent with previous studies, suggest that maternal serum RNLS levels are reduced in cases of preeclampsia. Interestingly, this was driven by the acid-sensitive fraction of serum RNLS and limited to preterm cases of PEC. Furthermore, while PEC diagnosis did not correlate with levels of RNLS within the placental villi, in the decidua and chorion layers RNLS levels were significantly reduced in preterm PEC compared to unaffected preterm deliveries. These findings help identify the potential correlation of maternal and fetal endogenous RNLS with the pathological development of the placenta and may suggest a possible therapeutic target for preeclampsia.

Results

RNLS level reduction in maternal serum is limited to preterm PEC

To investigate the role of RNLS in PEC, we measured the concentration of RNLS (ng/ml) using our validated ELISA in maternal serum samples from 28 patients²¹. These patients either had pregnancies effected by PEC and experienced either a preterm or term delivery. Samples were grouped into four cohorts: preterm preeclampsia (pPEC, n = 7), preterm without preeclampsia (preterm control, n = 6), term preeclampsia (tPEC, n = 4), and term without preeclampsia (term control, n = 11). Metadata for the samples used was collected and analyzed between the cohorts (supplementary Tables S1, S4 and S6). Although there was a slight imbalance in regards to sex and gestational age within the cohorts, none of the differences were statistically significant (Table S1). Furthermore, there was no difference between the cohorts when individual factors collected were analyzed (Supplementary Table S4, S6). The proportion of cases effected by chorioamnionitis was slightly higher in the control group compared to PEC, although not statistically significant ($p=0.07$). *Chorioamnionitis was the only factor that bordered on significance $p=0.07$ between the preterm PEC and preterm control groups (Table S6) and was higher in the control group than the PEC group (Supplementary Table S6)*. ELISA was performed on serum samples to determine the abundance of the two forms of RNLS, acid sensitive (protein-bound fraction) and native (active fraction) RNLS, between the four groups. We observed a notable reduction in the acid sensitive RNLS concentration but not the native RNLS in pPEC serum compared to preterm control serum without a difference between term samples (Fig. 1A). The relative proportion of native and acid sensitive RNLS fractions in maternal serum was associated with the length of gestation. There was a higher concentration of acid sensitive RNLS in preterm deliveries compared to term deliveries while the proportion of native RNLS was higher in term than preterm cases, independent of a PEC diagnosis (Fig. 1B, C). We performed Spearman correlation analysis to determine if gestational age directly influenced the RNLS levels in our serum samples and in our analysis for the gestational ages available, there was no correlation between GA and either the native, acid-sensitive, nor total serum RNLS levels in either the pPEC or preterm control cohorts (Fig. S1).

RNLS levels vary between placental layers

To further explore where RNLS is expressed in the placenta and if there is a correlation between PEC and RNLS levels in the placental tissue beyond maternal serum, we collected 19 placentas from preterm and term pregnancies with and without PEC. Samples were grouped into four cohorts: preterm preeclampsia (pPEC, n = 5), preterm without preeclampsia (preterm control, n = 4), term preeclampsia (tPEC, n = 5), and term without preeclampsia (term control, n = 5). Although there was a slight imbalance regarding sex and gestational age within the cohorts, none of the differences were statistically significant (Table S2, S5). The placental tissue was separated into the decidua, chorion and placental villi components. RNLS levels were labeled via an immunohistochemistry (IHC) stain with our m28-RNLS antibody. When the mean grey values were compared across the various layers of the placenta, both the interstitium and trophoblast layers of the placental villi expressed significantly higher RNLS than both the decidua and chorionic components. Notably, no significant differences were observed between interstitium and trophoblast sections of either the chorion or the placental villi. (Fig. 2A). Comparing the average mean grey value across the placental layers between the pPEC, preterm control, tPEC, and term control cohorts, similar trends were observed between layers within a particular cohort (Table S3).

RNLS levels are reduced in the decidua affected by PEC

From the representative images of the decidua in the four groups, it appeared that the labeling in the preeclampsia groups was lighter than in those resulting from pregnancies not effected by PEC (Fig. 3A-D). Upon




Fig. 1. RNLS levels reduced in maternal serum in preterm cases with PEC. **(A)** ELISAs performed on 28 maternal serum samples display the RNLS abundance (ng/ml) for the native and acid sensitive fractions. **(B)** The ratio native RNLS to acid sensitive RNLS present in maternal serum per each cohort—pPEC, preterm control, tPEC, and term control. **(C)** Grouped ratio of native RNLS to acid sensitive RNLS of preterm and term samples. * Reflects a p -value ≤ 0.05 . pPEC—preterm preeclampsia, preterm control—preterm without preeclampsia, tPEC—term preeclampsia, and term control—term without preeclampsia. Preterm PEC (n = 7), Preterm Control (n = 6), Term PEC (n = 4), and Term Control (n = 11). The bar graphs represent the mean values, and the error bars indicate Standard Error of the Mean.

quantification of the labeling intensities, we observed a significant reduction in RNLS levels amongst placentas of patients diagnosed with PEC (Fig. 3E). Interestingly, unlike in the maternal serum, where RNLS levels were only reduced in preterm PEC cases, with in the decidua, RNLS levels were reduced in both preterm and term deliveries effected by PEC (Fig. 3E).




Fig. 2. RNLS levels compared across placental layers and elevated in placental villi. (A) The RNLS expression per high powered field comparing the following placental layers: decidua, chorionic interstitium, chorionic trophoblasts, placental villi interstitium, and placental villi trophoblasts. Each point reflects the mean RNLS expression per high powered field and each placental layer contains all RNLS values regardless of cohort (PP, Preterm Control, TP, Term Control, $n = 19$) ** Reflects a p -value ≤ 0.01 and **** Reflects a p -value ≤ 0.0001 . The bar graphs represent the mean values, and the error bars indicate Standard Error of the Mean. Decidua ($n = 17$), Chorionic Interstitium ($n = 17$), Chorionic Trophoblasts ($n = 17$), PV Interstitium ($n = 19$), and PV Trophoblasts ($n = 19$).

RNLS levels within the chorionic layer of the placenta are decreased in preterm cases of PEC

We then examined if RNLS levels were altered within the fetal membranes in preterm and full-term cases effected by PEC. Visually, there was a reduction in the levels of RNLS in the cases of preterm deliveries effected by PEC compared to all other cases (Fig. 4A–D). This was confirmed by the quantification of the RNLS labeling that demonstrated a significant reduction in RNLS levels in preterm cases effected by PEC but not the term cases (Fig. 4E). This was particularly driven by the levels of RNLS in the chorionic trophoblasts (Fig. 4F). Notably, the RNLS expression of the pPEC cohort was $\sim 2 \times$ less than the RNLS expression of the preterm control cohort in both the chorionic interstitium and chorionic trophoblasts (Table S3).

PEC diagnosis is not associated with variable RNLS levels in the placental villi

Finally, we investigated if the levels of RNLS were altered within the placental villi. Similar to our previously published results, we were able to detect RNLS both in the placental villi trophoblasts and in the interstitium of the placental villi⁸. Visually, we did not observe any difference in the amount of RNLS present within the placental villi between any of the four cohorts (Fig. 5A–D). This was confirmed upon quantification of the labeling, where there was no observed difference in RNLS levels between pPEC, preterm control, tPEC, and term control groups (Fig. 5E). This was also the case when we examined the trophoblast and interstitial components of the placental villi separately (Fig. 5E, F).

Discussion

Preeclampsia (PEC) is a placental disease associated with hypertension, proteinuria, signs of uteroplacental dysfunction, or end-organ damage that can result in many complications for the maternal–fetal dyad alongside maternal risk of eclampsia^{1,2,7}. Previous studies have shown an association between PEC and shallow placentation, systemic inflammation, and oxidative stress⁷. Given that the only known cure for PEC is the delivery of the fetus¹, our investigation aimed to identify novel factors that influence the pathophysiology of PEC.




Fig. 3. RNLS levels are reduced in the decidua samples affected by PEC. (A–D) Labeling for RNLS with m28 antibodies in decidua samples. Scale bar is 110 μ m. Scale bar for inset is equivalent to 22 μ m. (E) The RNLS expression per high powered field comparing pPEC, preterm control, tPEC, and term control in the decidua. * Reflects a p -value ≤ 0.05 . pPEC–preterm preeclampsia, preterm control–preterm without preeclampsia, tPEC–term preeclampsia, and term control–term without preeclampsia. The bar graphs represent the mean values, and the error bars indicate Standard Error of the Mean. Preterm PEC (n=5), Preterm Control (n=3), Term PEC (n=4), and Term Control (n=5).




Fig. 4. RNLS levels are reduced in the fetal membranes of preterm samples with PEC. (A–D) Labeling for RNLS with m28 antibodies in fetal membranes samples. Scale bar is 110 μ m. Scale bar for inset is 15 μ m. (E) The RNLS expression per high powered field comparing pPEC, preterm control, tPEC, and term control in the chorionic interstitium. (F) The RNLS expression per high powered field comparing pPEC, preterm control, tPEC, and term control in the chorionic trophoblast. * Reflects a p -value ≤ 0.05 . pPEC–preterm preeclampsia, preterm control–preterm without preeclampsia, tPEC–term preeclampsia, and term control–term without preeclampsia. The bar graphs represent the mean values, and the error bars indicate Standard Error of the Mean. Both Chorion Interstitium and Trophoblasts have Preterm PEC (n = 5), Preterm Control (n = 3), Term PEC (n = 4), and Term Control (n = 5).




Fig. 5. Placental Villi RNLS levels are not altered by PEC. (A–D) Labeling for RNLS with m28 antibodies in placental villi samples at 20x. Scale bar is equivalent to 110 μ m. Scale bar for inset is equivalent to 15 μ m. (E) The RNLS expression per high powered field comparing pPEC, preterm control, tPEC, and term control in the placenta villi interstitium. (F) The RNLS expression per high powered field comparing pPEC, preterm control, tPEC, and term control in the placenta villi trophoblast. * Reflects a p -value ≤ 0.05 . pPEC–preterm preeclampsia, preterm control–preterm without preeclampsia, tPEC–term preeclampsia, and term control–term without preeclampsia. The bar graphs represent the mean values, and the error bars indicate Standard Error of the Mean. Preterm PEC (n=5), Preterm Control (n=4), Term PEC (n=5), and Term Control (n=5).

Renalase (RNLS) is a secretory flavoprotein that was initially identified to be secreted by the kidneys⁷ and has since been shown to be produced by several other organs^{6–8}. It functions as a pro-survival, anti-inflammatory, growth-promoting factor with cellular antioxidative properties¹⁰. It also has roles in regulation of blood pressure^{22,23}. Its role in pregnancy is unknown, but baseline serum RNLS levels are elevated during pregnancy¹¹. Furthermore, consistent with other disorders including: systemic hypertension and renal disease, preeclampsia has been associated with reduced RNLS levels^{6,10,11}. Recently, our group found that RNLS is endogenously produced by the placenta including in placental trophoblasts and Hofbauer cells, resident placental macrophages⁸.

To date, no studies have assessed the role of RNLS in pathological placentas and while there are a few studies which have associated reduced serum RNLS and PEC^{9–12}, it remains unknown whether this is different between preterm and term cases. Furthermore, it is unclear if either the native RNLS or acid sensitive RNLS fraction drives this reduction. As such we aimed to determine if there is an association between RNLS and PEC in placental tissue. Moreover, if the timing of the onset of PEC is related to either serum or placental levels of RNLS.

To determine if the biologically active RNLS form versus total RNLS reserve levels from maternal serum correlate with different presentations of PEC, we examined the acid sensitive and native RNLS fractions in preterm pregnancies with and without PEC and full-term pregnancies with and without PEC. An association of RNLS levels with PEC was only observed in preterm pregnancies where preterm serum samples affected by PEC had reduced levels of RNLS compared to preterm samples unaffected by PEC and were delivered for other indications. Interestingly, only the acid sensitive fraction was affected suggesting reduced total RNLS reserve in pPEC; the native form of serum RNLS was similar between cases with and without PEC. While the specific mechanisms resulting in PEC remain unknown, our finding that the acid sensitive fraction expressed in pPEC samples was notably lower than in preterm control samples, in combination with the acid sensitive fraction accounting for the majority of maternally available RNLS in preterm samples, may imply that a deficiency in the acid sensitive RNLS fraction either leads to or can serve as a marker of more severe PEC in early pregnancy. Additionally, we observed from our analysis that gestational age does not drive the observed reduction in the acid sensitive fraction of RNLS in the pPEC samples compared to the preterm control cohort. Furthermore, given the observed association between PEC and lower serum RNLS levels, it is possible that the elevated blood pressure and heightened inflammatory states observed in PEC are due to decreased serum RNLS levels. This is potentially secondary to increased RNLS consumption as a compensatory mechanism of PEC. Alternatively, the reduced abundance of acid sensitive RNLS in the maternal serum of pPEC samples may be partially explained by insufficient endogenous production of RNLS by various RNLS producing tissue.

Overall, the RNLS labeling was highest in the placental villi compared to both the decidua and the fetal membranes. When we examined the association between RNLS levels in various compartments of the placenta and PEC, we observed a reduction of RNLS associated with both preterm and term PEC within the decidua. However, the chorionic membrane expressed reduced levels of RNLS only in preterm cases, while the levels of RNLS within the placental villi were not affected by PEC. The observed reduction in RNLS levels in the maternal decidua and chorion in preterm cases of PEC suggested that the levels of RNLS are altered in PEC not only systemically but also locally in the placenta. Interestingly, levels of RNLS were reduced in the decidua in cases of PEC irrespective of gestational age, suggesting that local production or accumulation of RNLS at the maternal fetal interface is necessary throughout pregnancy and not just early gestation since even in term cases decreased levels of RNLS are associated with placental abnormalities. However, fetal membranes only demonstrated RNLS labeling reductions in preterm and not term cases, like the observations made in the maternal serum. This potentially suggests that RNLS activity is necessary throughout pregnancy at the site of implantation. Interestingly, we did not observe an association in RNLS levels in the placental villi neither in the trophoblasts or the interstitial with PEC in preterm or term cases even though the placental villi had the highest labeling for RNLS. This either suggests that PEC preferentially affects maternal rather than fetal tissue or that RNLS production within the placental villi is highly dynamic and is modulated in response to the increased consumption of RNLS in cases of PEC.

This is the first study to investigate RNLS levels in both serum and placental tissues in pregnancy and correlate them with PEC, addressing the knowledge gaps in PEC pathophysiology. The study also builds on previous work and provides a correlation of RNLS levels with early and late onset PEC in preterm and term deliveries which is an important step in elucidating the role of RNLS in successful pregnancy. Comparing the levels of RNLS among the three compartments of the placenta and its correlation with PEC in preterm and term deliveries, provided robust data on the potential role of RNLS as a biomarker or therapeutic target for preterm PEC, given its known role in blood pressure regulation. However, there are several limitations to the study, primarily its small sample size. Additionally, only one center was included in the study, and as such the generalizability of the study to other populations is unknown. Furthermore, we were unable to obtain matching placental tissue and serums from all subjects making it challenging to correlate serum and placental RNLS levels directly. Additionally, when assessing possible sources of confounding in the cohorts, none of the individual comparisons between the PEC and nPEC cohorts were significant, however multivariate analysis should be performed in the future. Chorioamnionitis was the only factor that bordered on significance $p=0.07$ between the preterm PEC and preterm control groups in the serum analysis having a higher proportions of samples effected by the condition in the control group. We cannot determine whether the Renalase values were higher with chorioamnionitis or lower with PEC from this particular cohort. However, given that no statistical differences were observed in the placental cohorts and similar RNLS trends were noted, it is more likely that the level of RNLS is decreased with PEC rather than increased with chorioamnionitis. A dedicated analysis of a preterm cohort with and without chorioamnionitis in the absence of PEC is needed to address that question.

In summary, we show that RNLS in maternal serum and some components of placental tissue is associated with PEC. These changes may be indicative of PEC severity and would position RNLS as a potential marker for PEC diagnosis that should be evaluated in future studies.

Methods

Maternal serum procurement and processing

Maternal peripheral blood samples were collected by Yale University Reproductive Sciences (YURS) Biobank, centrifuged for serum which was removed and frozen prior to use. For peripheral blood collection intended for serum samples, serum separation tubes (SST) were used. These tubes contain a gel that aids in separating the serum from the blood cells after centrifugation. Informed consent was obtained from all subjects. The study was approved by the Yale Institutional Review Boards (IRB) (HIC#1,309,012,696; IRB# 2,000,027,134). All the experimental protocols were performed in accordance with relevant guidelines and regulations. Metadata associated with these samples were collected and included: maternal age, BMI, GA at delivery, GA at serum collection, mode of delivery, smoking, PEC with severe features, prenatal steroid use, chronic HTN, pregnancy related HTN, kidney disease, UTI, autoimmune disease, GDM, chorioamnionitis and FGR (Table S4). BMI-body mass index, GA-gestational age, PEC-preeclampsia, HTN-hypertension, UTI-urinary tract infection, GDM-gestational diabetes meletus, FGR-fetal growth retardation.

ELISA

28 maternal serum samples from pPEC (n=7), preterm control (n=6), tPEC (n=4), and term control (n=11) patients were de-identified prior to distribution. Cohorts were balanced based on average gestation and sex (Table S1). ELISA was performed as we have described²¹. Plates were coated with m42-RNLS and incubated overnight at room temperature. Serum samples were either treated with or without 0.33 M citric acid for 15 min followed by a neutralization step with 0.4 M Na₂PO₄. Serum samples were added to the plates, diluted 1:1 with Diluent100, and incubated overnight at room temperature. Subsequent to 3 washes, a 1:1000 dilution of ab31291 was added to the plates and incubated at room temperature for 1 h prior to 3 additional washes. Finally, a 1:1000 dilution of Sulfo-tagged anti-goat was used to indicate abundance RNLS antigen. RNLS values from samples without acid-treatment were defined as native RNLS whereas samples treated with acid were defined as acid sensitive RNLS. The latter may represent a circulating RNLS fraction that is tightly bound to other proteins or RNLS multimers.

Placenta tissue procurement and processing

Placental samples were collected by Yale University Reproductive Sciences (YURS) Biobank, separated into the distinct layers of the placenta including: the decidua, chorion, and placental villi and formalin fixed. The biobank identified available cases of pPEC and tPEC and matched these to preterm control and term control based on sex and gestational age. All diagnoses of preeclampsia were made according to the guidelines established by the American College of Obstetricians and Gynecologists (ACOG). The control group consists of healthy individuals with uncomplicated pregnancies. All samples without preeclampsia were subjects without any major hypertensive, metabolic disease, known congenital fetal anomalies, birth weight between 10th and 90th percentile, abnormal growth, placental abnormalities, infections, singleton gestation, nor illicit/licit substance use. Cohorts were balanced based on average gestational and sex (Table S2). Metadata associated with these samples were collected and included: maternal age, BMI, GA at delivery, GA at serum collection, mode of delivery, smoking, PEC with severe features, prenatal steroid use, chronic HTN, pregnancy related HTN, kidney disease, UTI, autoimmune disease, GDM, chorioamnionitis and FGR (Table S5). BMI-body mass index, GA-gestational age, PEC-preeclampsia, HTN-hypertension, UTI-urinary tract infection, GDM-gestational diabetes meletus, FGR-fetal growth retardation.

Immunohistochemistry

19 formalin-fixed and paraffin-embedded placental samples from pPEC (n=5), preterm control (n=4), tPEC (n=5), and term control (n=5) patients were sectioned and mounted by Yale Histology Core. Slides were deparaffinized and rehydrated in ethanol prior to antigen retrieval using 10 mM citrate-buffered saline in a pressure cooker at 95 °C for 20 min. Sections were washed with TBS-Tween (1%) with 300 mM NaCl prior to blocking with DAO Dual Endogenous Enzyme Block for Autostainer for 10 min followed by blocking with 2.5% horse serum for 1 h (Agilent, Santa Clara, CA, USA). Slides were incubated with m28-RNLS (1:250 in TBS) overnight at 4 °C and incubated in secondary antibody IMPRESS Reagent anti-Rabbit IgG for 45 min (Vector Laboratories, Burlingame, CA, USA). Antibody detection was performed with Vector's ImmPACT DAB substrate kit prior to a hematoxylin counterstain (Vector Laboratories, Burlingame, CA, USA).

Image acquisition and quantification

IHC images were acquired on the Echo Revolve microscope using 20× objectives. Post-acquisition, images were color-balanced in Adobe Photoshop to normalize the image backgrounds prior to color deconvolution in Fiji's ImageJ using the H-DAB vector. The mean grey value of each IHC image was quantified by exclusively selecting the relevant tissue section of each sample present in the high-powered field which served as a metric of RNLS abundance. 3 distinct images were captured for each sample and the mean grey value for each image was averaged to determine a representative RNLS value for each sample.

Statistical analysis

Statistical analysis was conducted using Prism GraphPad 8. Serum RNLS abundances (ng/mL) were compared using the one-way ANOVAs. The proportionality comparison between abundance of native RNLS to acid sensitive RNLS underwent a two-way ANOVA. All mean gray values collected from the IHC images were compared using a non-parametric t-test (Mann-Whitney test) and significance was determined at a threshold of $p \leq 0.05$. We accounted for sex-based differences within each cohort and observed a no significant sex driven differences.

Additionally, average gestational age between preterm and term cohorts were consistent and demonstrated no statistically significant differences.

Correlation analysis between gestational age and serum renalase levels

Statistical analysis was conducted using Prism GraphPad 8. Native RNL (ng/mL), Acid Sensitive RNLS (ng/mL), and total RNLS (ng/mL) were individually compared to gestational age (weeks) in the preterm preeclamptic (pPEC) and preterm control cohorts using Spearman correlation. Weak correlation was defined as $r < 0.39$, moderate correlation was defined as $0.4 < r < 0.59$, and strong correlation was defined as $r > 0.6$ and significance was determined at a threshold of $p \leq 0.05$. (Fig S1).

Analysis of difference between cohorts for the ELISA and placenta samples

Statistical analysis was conducted using Prism GraphPad 8 for both ELISA and placental samples in which individual unpaired, nonparametric, Mann–Whitney t-tests between the preeclampsia (PEC) cohort and control (nPEC) cohort for both preterm and term cases. Categories including BMI (“Body Mass Index”), HTN (“Hypertension”), GA (“Gestational Age”), UTI (“Urinary Tract Infection”), GDM (“Gestational Diabetes Mellitus”), and FGR (“Fetal Growth Restriction”) were compared for both serum (Table S4 & Table S6) and placental samples (Table S5 & Table S7).

Data availability

The data that supports the findings present in this study are available upon request from the corresponding author.

Received: 24 April 2024; Accepted: 13 February 2025

Published online: 22 February 2025

References

1. Fox, R., Kitt, J., Leeson, P., Aye, C. Y. L. & Lewandowski, A. J. Preeclampsia: Risk factors, diagnosis, management, and the cardiovascular impact on the offspring. *J. Clin. Med.* **8**(10), 1625. <https://doi.org/10.3390/jcm8101625> (2019).
2. Burton, G. J., Redman, C. W., Roberts, J. M. & Moffett, A. Pre-eclampsia: pathophysiology and clinical implications. *BMJ* **366**, l2381. <https://doi.org/10.1136/bmj.l2381> (2019).
3. Amaral, L. M., Wallace, K., Owens, M. & LaMarca, B. Pathophysiology and current clinical management of preeclampsia. *Curr. Hypertens. Rep.* **19**(8), 61. <https://doi.org/10.1007/s11906-017-0757-7> (2017).
4. Odegård, R. A., Vatten, L. J., Nilsen, S. T., Salvesen, K. A. & Austgulen, R. Preeclampsia and fetal growth. *Obstet. Gynecol.* **96**(6), 950–955 (2000).
5. Weiler, J., Tong, S. & Palmer, K. R. Is Fetal growth restriction associated with a more severe maternal phenotype in the setting of early onset pre-eclampsia? A retrospective study. *PLOS ONE* **6**(10), e26937. <https://doi.org/10.1371/journal.pone.0026937> (2011).
6. Xu, J. et al. Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure. *J. Clin. Invest.* **115**(5), 1275–1280. <https://doi.org/10.1172/JCI24066> (2005).
7. Gao, Y. et al. Renalase is a novel tissue and serological biomarker in pancreatic ductal adenocarcinoma. *PloS One*. **16**(9), e0250539. <https://doi.org/10.1371/journal.pone.0250539> (2021).
8. Toothaker, J. M. et al. Immune landscape of human placental villi using single-cell analysis. *Development* **149**(8), dev200013. <https://doi.org/10.1242/dev.200013> (2022).
9. Bağcı, B., Karakus, S., Bağcı, G. & Sancakdar, E. Renalase gene polymorphism is associated with increased blood pressure in preeclampsia. *Pregnancy Hypertens Int J Womens Cardiovasc Health.* **6**(2), 115–120. <https://doi.org/10.1016/j.preghy.2016.04.002> (2016).
10. Desir, G. V. & Peixoto, A. J. Renalase in hypertension and kidney disease. *Nephrol. Dial. Transpl. Off. Publ. Eur. Dial Transpl. Assoc. Eur. Ren. Assoc.* **29**(1), 22–28. <https://doi.org/10.1093/ndt/gft083> (2014).
11. Yılmaz, Z. V., Akkaş, E., Yıldırım, T., Yılmaz, R. & Erdem, Y. A novel marker in pregnant with preeclampsia: Renalase. *J. Matern-Fetal Neonatal. Med. Off. J. Eur. Assoc. Perinat. Med. Fed. Asia Ocean Perinat. Soc. Int. Soc. Perinat. Obstet.* **30**(7), 808–813. <https://doi.org/10.1080/14767058.2016.1186637> (2017).
12. Baykus, Y. et al. Direct laboratory evidence that pregnancy-induced hypertension might be associated with increased catecholamines and decreased renalase concentrations in the umbilical cord and mother's blood. *J. Lab. Med.* **43**(2), 77–85. <https://doi.org/10.1515/labmed-2018-0185> (2019).
13. Herrick EJ, Bordoni B. Embryology, Placenta. In: *StatPearls*. StatPearls Publishing; 2024. Accessed March 11, 2024. <http://www.ncbi.nlm.nih.gov/books/NBK551634/>
14. Knöfler, M. et al. Human placenta and trophoblast development: Key molecular mechanisms and model systems. *Cell Mol. Life Sci.* **76**(18), 3479–3496. <https://doi.org/10.1007/s00018-019-03104-6> (2019).
15. Jena, M. K., Sharma, N. R., Petitt, M., Maulik, D. & Nayak, N. R. Pathogenesis of Preeclampsia and Therapeutic Approaches Targeting the Placenta. *Biomolecules.* **10**(6), 953. <https://doi.org/10.3390/biom10060953> (2020).
16. Balasundaram P, Farhana A. Immunology at the Maternal-Fetal Interface. In: *StatPearls*. StatPearls Publishing; 2024. Accessed March 11, 2024. <http://www.ncbi.nlm.nih.gov/books/NBK574542/>
17. Blundell, C. et al. A microphysiological model of the human placental barrier. *Lab. Chip.* **16**(16), 3065–3073. <https://doi.org/10.1039/c6lc00259e> (2016).
18. Mori, M., Bogdan, A., Balassa, T., Csabai, T. & Szekeres-Bartho, J. The decidua—the maternal bed embracing the embryo—maintains the pregnancy. *Semin. Immunopathol.* **38**(6), 635–649. <https://doi.org/10.1007/s00281-016-0574-0> (2016).
19. Wang Y, Zhao S. Cell Types of the Placenta. In: *Vascular Biology of the Placenta*. Morgan & Claypool Life Sciences; 2010. Accessed March 11, 2024. <https://www.ncbi.nlm.nih.gov/books/NBK53245/>
20. Kapila V, Chaudhry K. Physiology, Placenta. In: *StatPearls*. StatPearls Publishing; 2024. Accessed March 11, 2024. <http://www.ncbi.nlm.nih.gov/books/NBK538332/>
21. Chang, J. et al. Identification of two forms of human plasma renalase, and their association with all-cause mortality. *Kidney Int. Rep.* **5**(3), 362–368. <https://doi.org/10.1016/j.ekir.2019.12.002> (2020).
22. Wang, Y. et al. Associations of renalase with blood pressure and hypertension in chinese adults. *Front. Cardiovasc. Med.* **9**, 800427. <https://doi.org/10.3389/fcvm.2022.800427> (2022).
23. Desir, G. V. et al. Renalase lowers ambulatory blood pressure by metabolizing circulating adrenaline. *J. Am. Heart Assoc.* **1**(4), e002634. <https://doi.org/10.1161/JAHA.112.002634> (2012).

Acknowledgements

The authors would like to thank Dr. Fred Gorelick for his scientific contributions and careful review of this manuscript. We thank the Yale University Reproductive Service Biobank for their help with collecting both the maternal peripheral blood serum samples and the placental tissue samples.

Author contributions

L.K. secured funding for the project. L.K. and G.D. conceived and supervised the work. M.W. identified the cohort of subjects and procured the samples. X.G. performed the renalase ELISA experiments. C.K.E., T.S., and Y.S. performed all the IHC of placental tissue. C.K.E. and Y.S. analyzed all ELISA and IHC data. C.K.E. and Y.S. wrote the manuscript with edits by L.K. and all authors contributed to the final draft. C.K.E. and Y.S. are equal co-first authors.

Funding

L.K. is supported by Yale University start-up funds and NIH Grants R21TR002639, R21HD102565, R01AI171980, R01DK129552, and R01HL163043.

Declarations

Competing interests

G.D. is a named inventor on several issued patents related to the discovery and therapeutic use of renalase. Renalase is licensed to Bessor Pharma, and G.D. holds an equity position in Bessor and its subsidiary Personal Therapeutics. All other authors do not have any competing interests to disclose.

Additional information

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1038/s41598-025-90524-z>.

Correspondence and requests for materials should be addressed to L.K.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

© The Author(s) 2025